Mechanisms of disease: Pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 4, 2005, Pages 209-216

  Díez, Javier ^a   González, Arantxa ^a   López, Begoña ^a   Querejeta, Ramón ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

Author keywords

Arterial hypertension; Collagen; Fibrosis; Left venticular hypertrophy

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FENOFIBRATE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; SPIRONOLACTONE; TRANILAST;

COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; HEART HEMODYNAMICS; HEART MUSCLE FIBROSIS; HEART VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MYOFIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

COLLAGEN TYPE I; COLLAGEN TYPE III; FIBROSIS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 20444498653     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0158     Document Type: Review

References (57)

1. Tanaka M et al. (1986) Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 55: 575-581
2. Olivetti G et al. (1994) Myocyte cellular hypertrophy is responsible for ventricular remodeling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res 28: 1199-1208
3. Rossi MA (1998) Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 16: 1031-1041
4. Ciulla M et al. (1997) Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 10: 657-664
5. Schwartzkopff B et al. (2000) Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 36: 220-225
6. Brilla CG et al. (2000) Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102: 1388-1393
7. Querejeta R et al. (2000) Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101: 1729-1735
8. Weber KT (2000) Fibrosis and hypertensive heart disease. Curr Opin Cardiol 15: 264-272
9. Varo N et al. (1999) Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 17: 107-114
10. 1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 35: 1197-1202
11. Bishop JE and Lindahl G (1999) Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Pes 42: 27-44
12. López B et al. (2004) Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertens 13:197-204
13. Wakatsuki T et al. (2004) The biochemical reponse of the heart to hypertension and exercise. Trends Biochem Sci 29: 609-617
14. Amanuma S et al. (1994) Biventricular endomyocardial biopsy findings in essential hypertension of graded severity. Postgrad Med J 70 (Suppl 1): S67-S71
15. Pearlman ES et al. (1982) Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest 46: 158-164
16. Boldt A et al. (2004) Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 90: 400-405
17. López B et al. (2001) Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 104: 286-291
18. Díez J et al. (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105: 2512-2517
19. González A et al. (2002) Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol 34: 1585-1593
20. Díez J (2004) Profibrotic effects of angiotensin II in the heart: a matter of mediators. Hypertension 43: 1164-1165
21. Tokuda K et al. (2004) Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 43: 499-503
22. Yoshida J et al. (2004) AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic failure. Hypertension 43: 686-691
23. Lijnen P and Petrov V (2000) Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 32: 865-879
24. Brilla CG et al. (1993) Antifibrotic effect of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardfol 71: 12A-16A
25. Brilla CG et al. (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26: 809-820
26. Rocha R et al. (2002) Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143: 4828-4836
27. Iglarz M et al. (2004) Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system. Am J Hypertens 17: 597-603
28. Kuster GM et al. (2005) Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 111: 420-427
29. Ahokas RA et al. (2003) Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res 93: e124-e135
30. Jacob HJ et al. (1991) Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell 67: 213-224
31. Challah M et al. (1998) Angiotensin I-converting enzyme genotype influences arterial response to injury in normotensive rats. Arterioscler Thromb Vasc Biol 18: 235-243
32. Ocaranza MP et al. (2004) Polymorphism in gene coding for ACE determines different development of myocardial fibrosis in rats. Am J Physiol Heart Circ Physiol 286: H498-H506
33. 1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens 21: 2085-2092
34. Frohlich ED (2001) Fibrosis and ischemia: the real risks in hypertensive heart disease. Am J Hypertens 14: 194S-199S
35. Burlew BS and Weber KT (2002) Cardiac fibrosis as a cause of diastolic dysfunction. Herz 27: 92-98
36. Burlew BS and Weber KT (2000) Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin 18: 435-442
37. Ohsato K et al. (1992) Histopathologic factors related to diastolic function in myocardial hypertrophy. Jpn Circ J 56: 325-333
38. McLenachan JM and Dargie JH (1990) Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relation to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 3: 735-740
39. Querejeta R et al. (2004) Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110: 1263-1268
40. Schwartzkopff B et al. (1993) Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 88: 993-1003
41. Isoyama S et al. (1992) Collagen deposition and the reversal of coronary reserve in cardiac hypertrophy. Hypertension 20: 491-500
42. Bethge C et al. (1987) Ventricular arrhythmias in hypertensive heart disease with and without heart failure. J Cardiovasc Pharmacol 10 (Suppl 6): S119-S128
43. Nattel S (2004) Defining "culprit mechanisms" in arrhythmogenic cardiac remodeling. Circ Res 94: 1403-1405
44. Kannel WB et al. (1982) Epidemiologic features of chronic atrial fibrillation. The Framingham Study. N Engl J Med 306: 1018-1022
45. Tamirisa. PK et al. (2001) Ultrasonic tissue characterization: review of an approach to assess hypertrophic myocardium. Echocardiography 18: 593-597
46. Kerut EK et al. (2003) Review of methods for texture analysis of myocardium from echocardiographic images: a means of tissue characterization. Echocardiography 20: 727-736
47. Picano E et al. (1990) In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 81: 58-64
48. Moon JC and Prasad SK (2005) Cardiovascular magnetic resonance and the evaluation of heart failure. Curr Cardiol Rep 7: 39-44
49. Tandri H et al. (2005) Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 45: 98-103
50. López B et al. (2001) Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 38: 1222-1226
51. Díez J et al. (1996) Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 93: 1026-1032
52. Guidelines Committee (2003) European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053
53. Brilla CG et al. (1991) Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 83: 1771-1779
54. Kagitani S et al. (2004) Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens 22: 1007-1015
55. Rasoul S et al. (2004) Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 22: 593-603
56. Ogata T et al. (2004) Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferators-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 43: 1481-1488
57. Meiners S et al. (2004) Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 44: 471-477